Apellis Pharmaceuticals, Inc. $APLS Shares Bought by EFG Asset Management North America Corp.

EFG Asset Management North America Corp. raised its stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 166.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 105,024 shares of the company’s stock after purchasing an additional 65,661 shares during the quarter. EFG Asset Management North America Corp. owned 0.08% of Apellis Pharmaceuticals worth $1,817,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Assetmark Inc. lifted its holdings in shares of Apellis Pharmaceuticals by 3,938.7% during the first quarter. Assetmark Inc. now owns 1,252 shares of the company’s stock worth $27,000 after purchasing an additional 1,221 shares during the period. Parallel Advisors LLC raised its position in Apellis Pharmaceuticals by 80.0% during the 2nd quarter. Parallel Advisors LLC now owns 1,924 shares of the company’s stock worth $33,000 after buying an additional 855 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Apellis Pharmaceuticals by 15.6% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,855 shares of the company’s stock worth $84,000 after acquiring an additional 655 shares during the period. Amalgamated Bank lifted its stake in shares of Apellis Pharmaceuticals by 12.0% in the 2nd quarter. Amalgamated Bank now owns 8,111 shares of the company’s stock worth $140,000 after acquiring an additional 866 shares during the period. Finally, Legacy Capital Group California Inc. increased its stake in shares of Apellis Pharmaceuticals by 32.8% during the first quarter. Legacy Capital Group California Inc. now owns 9,554 shares of the company’s stock worth $209,000 after acquiring an additional 2,359 shares during the period. Hedge funds and other institutional investors own 96.29% of the company’s stock.

Apellis Pharmaceuticals Stock Down 2.5%

APLS opened at $19.95 on Thursday. The company has a debt-to-equity ratio of 0.90, a quick ratio of 3.16 and a current ratio of 3.54. The company has a market cap of $2.52 billion, a price-to-earnings ratio of 64.36 and a beta of 0.70. Apellis Pharmaceuticals, Inc. has a one year low of $16.10 and a one year high of $35.72. The business’s fifty day moving average is $25.06 and its two-hundred day moving average is $21.76.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its quarterly earnings results on Thursday, October 30th. The company reported $1.67 earnings per share for the quarter, beating analysts’ consensus estimates of $1.03 by $0.64. Apellis Pharmaceuticals had a return on equity of 18.94% and a net margin of 4.43%.The business had revenue of $458.58 million during the quarter, compared to analysts’ expectations of $364.58 million. During the same quarter last year, the business posted ($0.46) earnings per share. The business’s revenue for the quarter was up 133.0% on a year-over-year basis. Analysts anticipate that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Wall Street Analyst Weigh In

APLS has been the subject of a number of recent analyst reports. Robert W. Baird raised their price objective on shares of Apellis Pharmaceuticals from $50.00 to $52.00 and gave the company an “outperform” rating in a research report on Friday, October 31st. Raymond James Financial decreased their price target on Apellis Pharmaceuticals from $52.00 to $50.00 and set an “outperform” rating on the stock in a research note on Friday, August 1st. Wells Fargo & Company assumed coverage on Apellis Pharmaceuticals in a research report on Wednesday, October 15th. They issued an “overweight” rating and a $32.00 price objective for the company. Cantor Fitzgerald raised their target price on Apellis Pharmaceuticals from $39.00 to $40.00 and gave the company an “overweight” rating in a report on Friday, August 1st. Finally, JPMorgan Chase & Co. lowered their price target on shares of Apellis Pharmaceuticals from $40.00 to $36.00 and set an “overweight” rating on the stock in a research note on Wednesday. Nine research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $33.06.

Insider Buying and Selling at Apellis Pharmaceuticals

In other news, Director A. Sinclair Dunlop sold 31,092 shares of the stock in a transaction that occurred on Friday, October 10th. The shares were sold at an average price of $23.72, for a total value of $737,502.24. Following the sale, the director directly owned 3,837 shares in the company, valued at $91,013.64. This represents a 89.01% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, General Counsel David O. Watson sold 5,000 shares of Apellis Pharmaceuticals stock in a transaction that occurred on Thursday, October 16th. The stock was sold at an average price of $25.22, for a total value of $126,100.00. Following the transaction, the general counsel owned 113,730 shares of the company’s stock, valued at $2,868,270.60. This represents a 4.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 312,921 shares of company stock worth $8,490,866. 6.50% of the stock is currently owned by insiders.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).